Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC1 | P07992 | 1/20 | 0.50 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.50 |
| ▸ | DPYD | Q12882 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 9/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3069301 | 0.83 | MCL1 (0.58) | ERCC1ERCC4DPYDMCL1ALDH1A1 | |
| SCHEMBL4158371 | 0.72 | ERCC1 (0.43) | ERCC1ERCC4MCL1ALDH1A1PIK3CD | |
| SCHEMBL1038352 | 0.70 | — | — | |
| SCHEMBL1887803 | 0.67 | — | — | |
| SCHEMBL1853196 | 0.67 | — | — | |
| SCHEMBL620683 | 0.67 | — | — | |
| SCHEMBL9949061 | 0.67 | ERCC1 (0.50) | ERCC1ERCC4MCL1ALDH1A1CREBBP | |
| SCHEMBL2635489 | 0.67 | ERCC1 (0.50) | ERCC1ERCC4MCL1ALDH1A1CREBBP | |
| SCHEMBL17546137 | 0.64 | ERCC1 (0.52) | ERCC1ERCC4ALDH1A1HPGDCREBBP | |
| SCHEMBL11167009 | 0.63 | MCL1 (0.73) | ERCC1ERCC4DPYDMCL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090136448-A1 | Antiviral 2-Carboxy-Thiophene Compounds | CORFIELD JOHN ANDREW | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090136448-A1 | Antiviral 2-Carboxy-Thiophene Compounds | EIF2AK2, HAVCR2, MAVS | ERCC1 3809/4885ERCC4 3322/4885DPYD 1114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.